Free-text search
Articles per year:
Content Types
-
Lundbeck sells off factory in Italy
Lundbeck has sold its Italian facility and will center ingredient manufacturing at home soil.
-
Finnish biotech raises 28 million euros for next-generation allergy treatments
Finnish biotech Desentum is developing a new type of immunotherapy for some of the most common allergies. The company has just raised 28 million euros in an oversubscribed share issue to support its development efforts.
-
GSK to cut 1,200 jobs in Belgium
More than 1,200 jobs at UK pharma giant GSK are at risk in Belgium as part of a major cost-cutting drive.
-
Modus shares halve after safety-related trial pause
Swedish biotech Modus Therapeutics has temporarily paused recruitment to its Phase IIa trial in anaemia associated with chronic kidney disease following a serious event in a patient. The company’s share price halved after the announcement.
-
Swedish Life Science industry needs more than another funding wish list
When Swedish life science companies run into difficulties, calls for more public funding often follow. But do we really know what is holding these companies back – and whether current initiatives are addressing the right problems? In this opinion article, independent life science adviser Niklas Magnell asks whether Sweden is focusing on the right solutions.
-
Swedish electrode technology moves from lab to patients
Fractions of a millimetre can determine whether deep brain stimulation relieves symptoms or causes side effects. Now, after 20 years of research, scientists at Lund University are preparing to test Swedish-developed technology using ultra-thin electrodes in patients for the first time.
-
Oncopeptides raises SEK 100 million after brain cancer breakthrough
Swedish biotech Oncopeptides is raising SEK 100 million through a directed share issue. The announcement comes days after the company reported progress with its peptide-drug conjugate (PDC) platform in a new area: glioblastoma.
-
This is how Denmark wants to renegotiate the MDR
Danish health minister Ida Auken are heading to the EU to negotiate MDR, and Medtech Denmark are positive towards the government's position.
-
Teva wins FDA approval for schizophrenia injection
The US Food and Drug Administration (FDA) has approved Teva’s Weltruza, the first long-acting olanzapine injection that can be administered subcutaneously once a month to adults with schizophrenia.
-
Ambu expands their bronchoscopy offering
Ambu's bronchoscope offering has been cleared for use in the pediatric segment.
-
Xbrane reaches milestone with biosimilar to blockbuster cancer drug
Swedish biotech Xbrane is taking another step in developing a biosimilar to Bristol Myers Squibb’s blockbuster cancer drug Opdivo. All patients have now been enrolled in the pivotal trial, bringing the company closer to a potential multibillion-dollar market.
-
He helped build Oslo Cancer Cluster – now AI is his next challenge
After 12 years, Ketil Widerberg is stepping down as General Manager of Oslo Cancer Cluster. His next move takes him to Oslo University Hospital, where he will focus on artificial intelligence and healthcare.
-
Bristol Myers Squibb reports dual Phase III success
Bristol Myers Squibb has reported positive late-stage results for drug candidates targeting idiopathic pulmonary fibrosis and neuroendocrine tumours of the gastrointestinal tract and pancreas (GEP-NETs).
-
MMI raises $125M for robotic surgery
MMI, the maker of the Symani surgical robot, has completed a $125 million funding round.
-
Camurus takes next step with Oczyesa – wins Canadian approval
Swedish pharmaceutical company Camurus has secured another marketing approval for its acromegaly treatment. Canada has now approved Oczyesa XR, which patients can inject themselves once a month.
-
Per-Ola Carlsson honoured for diabetes research
Professor Per-Ola Carlsson, of Uppsala University and Akademiska sjukhuset, has been awarded the 2026 Kerstin Brismar Award, which includes a research grant of SEK 500,000.
-
Decision on rival CAR-T therapies: Yes to Yescarta, no to Breyanzi
Sweden’s Council for New Therapies (NT-rådet) has assessed two CAR-T therapies for follicular lymphoma, reaching very different conclusions.
-
Swedish medtech firm misses out on EU funding – files for bankruptcy
The Lund-based medical technology company NanoEcho has filed for bankruptcy following financial difficulties.
-
Labour drug shortage in Sweden could be fixed by looking towards Denmark
Important labour ward drug is being discontinued in Sweden, but Denmark has already found a solution.
-
Abbott gets FDA nod for updated heart failure system
Abbott has received approval from the U.S. Food and Drug Administration (FDA) for updates to its implantable heart monitoring system.
-
Viatris to buy Pacira for $1.65 billion
Viatris is acquiring Pacira BioSciences for $1.65 billion, strengthening its portfolio with two high-margin, non-opioid pain treatments.
-
Pfizer wins new FDA approval for Tukysa in breast cancer
Pfizer is strengthening its position in HER2-positive breast cancer. The FDA has approved Tukysa as a first-line maintenance treatment after a phase III trial showed that the combination extended progression-free survival by 8.6 months.
-
Danish Care call out Danish government: “The industry is ready”
The Danish sector for assistive devices and welfare technology is growing, but the improvement is uneven. Industry association calls for political action on the matter.
-
Roche's Tecentriq gets FDA nod after strong colon cancer data
A combination of Tecentriq and chemotherapy cut the risk of recurrence or death by half in patients with stage III colon cancer and dMMR tumours. The results have now paved the way for a new FDA approval.
BREAKING